ArticleJournal of applied physiology (Bethesda, Md. : 1985)2015
Duration of action of hypertonic saline on mucociliary clearance in the normal lung.
Article in Journal of applied physiology (Bethesda, Md. : 1985), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Acute Effect of E-Cigarette Inhalation on Mucociliary Clearance in E-Cigarette Users.Journal of aerosol medicine and pulmonary drug delivery · 2024Trial
- Effect of airway clearance therapies on mucociliary clearance in adults with cystic fibrosis: A randomized controlled trial.PloS one · 2022Trial
- Short course gamma tocopherol did not mitigate effects of ozone on airway inflammation in asthmatics.Inhalation toxicology · 2020Trial
- Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2018Trial
- Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in volunteers with asthma.The Journal of allergy and clinical immunology · 2018Trial
- Mucociliary and cough clearance in primary ciliary dyskinesia as affected by mutations inERJ open research · 2026Article
- Hypertonic thermal solutions as a putative strategy for respiratory biofilm disruption.Open medicine (Warsaw, Poland) · 2026Article
- Airway mucus in infection.Frontiers in physiology · 2026Review
- ODAD4-Related Primary Ciliary Dyskinesia: Report of Five Cases and a Founder Variant in Quebec.Cells · 2025Article
- Article
- Review
- Airway clearance in patients with neuromuscular disease.Paediatric respiratory reviews · 2023Review
- QuantitativeERJ open research · 2023Article
- Down-expression of Foxj1 on airway epithelium with impaired cilia architecture in non-cystic fibrosis bronchiectasis implies disease severity.The clinical respiratory journal · 2023Article
- Physiology and pathophysiology of human airway mucus.Physiological reviews · 2022Review
- The Role of Seawater and Saline Solutions in Treatment of Upper Respiratory Conditions.Marine drugs · 2022Review
- Hereditary Mucin Deficiency Caused by Biallelic Loss of Function ofAmerican journal of respiratory and critical care medicine · 2022Article
- Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-19.European journal of clinical pharmacology · 2021Review
- Acute and durable effect of inhaled hypertonic saline on mucociliary clearance in adult asthma.ERJ open research · 2021Article
- Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis.ERJ open research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Inhalation of hypertonic saline (HS) acutely enhances mucociliary clearance (MC) in both health and disease. In patients with cystic fibrosis (CF), repeated use of HS causes a sustained improvement in MC as well as clinical benefit. The pharmacodynamic duration of activity on MC may be an important determinant of its therapeutic potential in other airways diseases. Before moving toward testing the clinical benefits of HS for non-CF indications, we sought to assess the duration of pharmacodynamic effects of HS in healthy subjects by performing radiotracer clearance studies at baseline, 30-min post-HS administration, and 4-h post-HS administration. Indeed, acceleration of MC was observed when measured 30 min after HS inhalation. This acceleration was most pronounced in the first 30 min after inhaling the radiotracer in the central lung region (mean Ave30Clr = 15.5 vs. 8.6% for 30-min post-HS treatment vs. mean baseline, respectively, P < 0.005), suggesting that acute HS effects were greatest in the larger bronchial airways. In contrast, when MC was measured 4 h after HS administration, all indices of central lung region MC were slower than at baseline: Ave30Clr = 5.9% vs. 8.6% (P = 0.10); Ave90Clr = 12.4% vs. 16.8% (P < 0.05); clearance through 3 h = 29.4 vs. 43.7% (P < 0.002); and clearance through 6 h = 39.4 vs. 50.2% (P < 0.02). This apparent slowing of MC in healthy subjects 4-h post-HS administration may reflect depletion of airway mucus following acute HS administration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.